Literature DB >> 24725516

Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.

Sameer J Patel1, André P Oliveira2, Juyan Julia Zhou2, Luis Alba2, E Yoko Furuya3, Scott A Weisenberg4, Haomiao Jia5, Sarah A Clock2, Christine J Kubin6, Stephen G Jenkins7, Audrey N Schuetz8, Maryam Behta9, Phyllis Della-Latta10, Susan Whittier10, Kyu Rhee11, Lisa Saiman12.   

Abstract

BACKGROUND: Extremely drug-resistant gram-negative bacilli (XDR-GNB) increasingly cause health care-associated infections (HAIs) in intensive care units (ICUs).
METHODS: A matched case-control (1:2) study was conducted from February 2007 to January 2010 in 16 ICUs. Case and control subjects had HAIs caused by GNB susceptible to ≤1 antibiotic versus ≥2 antibiotics, respectively. Logistic and Cox proportional hazards regression assessed risk factors for HAIs and predictors of mortality, respectively.
RESULTS: Overall, 103 case and 195 control subjects were enrolled. An immunocompromised state (odds ratio [OR], 1.55; P = .047) and exposure to amikacin (OR, 13.81; P < .001), levofloxacin (OR, 2.05; P = .005), or trimethoprim-sulfamethoxazole (OR, 3.42; P = .009) were factors associated with XDR-GNB HAIs. Multiple factors in both case and control subjects significantly predicted increased mortality at different time intervals after HAI diagnosis. At 7 days, liver disease (hazard ratio [HR], 5.52), immunocompromised state (HR, 3.41), and bloodstream infection (HR, 2.55) predicted mortality; at 15 days, age (HR, 1.02 per year increase), liver disease (HR, 3.34), and immunocompromised state (HR, 2.03) predicted mortality; and, at 30 days, age (HR, 1.02 per 1-year increase), liver disease (HR, 3.34), immunocompromised state (HR, 2.03), and hospitalization in a medical ICU (HR, 1.85) predicted mortality.
CONCLUSION: HAIs caused by XDR-GNB were associated with potentially modifiable factors. Age, liver disease, and immunocompromised state, but not XDR-GNB HAIs, were associated with mortality.
Copyright © 2014 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Gram-negative bacteria; Health care-associated infection; Mortality

Mesh:

Substances:

Year:  2014        PMID: 24725516      PMCID: PMC4083852          DOI: 10.1016/j.ajic.2014.01.027

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  34 in total

1.  Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.

Authors:  Carlos Magno C B Fortaleza; Maristela P Freire; Djalma de C Moreira Filho; Marcelo de Carvalho Ramos
Journal:  Infect Control Hosp Epidemiol       Date:  2006-08-21       Impact factor: 3.254

2.  Resistant gram-negative bacilli: A neglected healthcare crisis?

Authors:  Ebbing Lautenbach; Ron E Polk
Journal:  Am J Health Syst Pharm       Date:  2007-12-01       Impact factor: 2.637

3.  Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection.

Authors:  Thomas P Lodise; Nimish Patel; Andrea Kwa; Jeffrey Graves; Jon P Furuno; Eileen Graffunder; Ben Lomaestro; Jessina C McGregor
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

Review 4.  Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Int J Antimicrob Agents       Date:  2007-02-16       Impact factor: 5.283

Review 5.  The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Matthew E Falagas; Patra K Koletsi; Ioannis A Bliziotis
Journal:  J Med Microbiol       Date:  2006-12       Impact factor: 2.472

6.  Risk factors for infections with multidrug-resistant Stenotrophomonas maltophilia in patients with cancer.

Authors:  Shoaib R Ansari; Hend Hanna; Ray Hachem; Ying Jiang; Kenneth Rolston; Issam Raad
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

7.  Cross-transmission of nosocomial pathogens in an adult intensive care unit: incidence and risk factors.

Authors:  M Halwani; M Solaymani-Dodaran; H Grundmann; C Coupland; R Slack
Journal:  J Hosp Infect       Date:  2006-03-03       Impact factor: 3.926

8.  Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.

Authors:  Galo Peralta; M Blanca Sánchez; J Carlos Garrido; Inés De Benito; M Eliecer Cano; Luis Martínez-Martínez; M Pía Roiz
Journal:  J Antimicrob Chemother       Date:  2007-07-20       Impact factor: 5.790

Review 9.  Does this patient have ventilator-associated pneumonia?

Authors:  Michael Klompas
Journal:  JAMA       Date:  2007-04-11       Impact factor: 56.272

10.  Relationship between immunosuppression and intensive care unit-acquired multidrug-resistant bacteria: a case-control study.

Authors:  Saad Nseir; Christophe Di Pompeo; Maimouna Diarra; Hélène Brisson; Stéphanie Tissier; Marie Boulo; Alain Durocher
Journal:  Crit Care Med       Date:  2007-05       Impact factor: 7.598

View more
  9 in total

Review 1.  Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients.

Authors:  Elisabeth Paramythiotou; Christina Routsi
Journal:  World J Crit Care Med       Date:  2016-05-04

2.  Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces.

Authors:  C Greene; J Wu; A H Rickard; C Xi
Journal:  Lett Appl Microbiol       Date:  2016-08-28       Impact factor: 2.858

3.  Increased multidrug resistant isolates: new clinical burdens for 66 hospitals in Shanghai, 2015 to 2017.

Authors:  Jiabing Lin; Xiaodong Gao; Yangwen Cui; Wei Sun; Yan Shen; Qingfeng Shi; Xiang Chen; Bijie Hu
Journal:  Ann Transl Med       Date:  2020-02

4.  Multidrug resistant Pseudomonas aeruginosa survey in a stream receiving effluents from ineffective wastewater hospital plants.

Authors:  Mary Joyce Targino Lopes Magalhães; Gemilson Pontes; Paula Takita Serra; Antonio Balieiro; Diogo Castro; Fabio Alessandro Pieri; James Lee Crainey; Paulo Afonso Nogueira; Patricia Puccinelli Orlandi
Journal:  BMC Microbiol       Date:  2016-08-24       Impact factor: 3.605

5.  Frequency of bap and cpaA virulence genes in drug resistant clinical isolates of Acinetobacter baumannii and their role in biofilm formation.

Authors:  Arezoo Fallah; Mohammad Ahangarzadeh Rezaee; Alka Hasani; Mohammad Hossein Soroush Barhaghi; Hossein Samadi Kafil
Journal:  Iran J Basic Med Sci       Date:  2017-08       Impact factor: 2.699

6.  Ethics of Infection Control Measures for Carriers of Antimicrobial Drug-Resistant Organisms.

Authors:  Babette Rump; Aura Timen; Marlies Hulscher; Marcel Verweij
Journal:  Emerg Infect Dis       Date:  2018-09       Impact factor: 6.883

7.  Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.

Authors:  Syed A K S Ahmed; Michelle Rudden; Thomas J Smyth; James S G Dooley; Roger Marchant; Ibrahim M Banat
Journal:  Appl Microbiol Biotechnol       Date:  2019-03-09       Impact factor: 4.813

8.  From Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB).

Authors:  Yiying Cai; Nathalie Grace Chua; Tze-Peng Lim; Jocelyn Qi-Min Teo; Winnie Lee; Asok Kurup; Tse-Hsien Koh; Thuan-Tong Tan; Andrea L Kwa
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

9.  Two years study of prevalence and antibiotic resistance pattern of Gram-negative bacteria isolated from surgical site infections in the North of Iran.

Authors:  Hossein Hemmati; Meysam Hasannejad-Bibalan; Sara Khoshdoz; Parisa Khoshdoz; Tofigh Yaghubi Kalurazi; Hadi Sedigh Ebrahim-Saraie; Soheila Nalban
Journal:  BMC Res Notes       Date:  2020-08-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.